Medtronic Plc (MDT) financial statements: income statement, balance sheet and cash flow
Medtronic Plc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Apr 24, 2026 · FY), Medtronic Plc reported revenue of $36.4B (+8.4% year on year) and net income of $4.8B (+3.1% year on year).
Income statement
Medtronic Plc income statement, fiscal years
Line item
Apr 24, 2026 · FY
Apr 25, 2025 · FY
Apr 26, 2024 · FY
Apr 28, 2023 · FY
Net sales
$36.4B
$33.5B
$32.4B
$31.2B
Cost of products sold, excluding amortization of intangible assets
$12.7B
$11.6B
$11.2B
$10.7B
Research and development expense
$2.9B
$2.7B
$2.7B
$2.7B
Selling, general, and administrative expense
$11.8B
$10.8B
$10.7B
$10.4B
Amortization of intangible assets
$1.8B
$1.8B
$1.7B
$1.7B
Restructuring charges, net
$249.0M
$267.0M
$226.0M
$375.0M
Certain litigation charges, net
$113.0M
$317.0M
$149.0M
($30.0M)
Other operating expense (income), net
$386.0M
($23.0M)
$464.0M
($131.0M)
Operating profit
$6.5B
$6.0B
$5.1B
$5.5B
Other non-operating expense (income), net
($384.0M)
($402.0M)
($412.0M)
($515.0M)
Interest expense, net
$715.0M
$729.0M
$719.0M
$636.0M
Income before income taxes
$6.1B
$5.6B
$4.8B
$5.4B
Income tax provision
$1.3B
$936.0M
$1.1B
$1.6B
Net income
$4.8B
$4.7B
$3.7B
$3.8B
Net income attributable to noncontrolling interests
($37.0M)
($29.0M)
($28.0M)
($26.0M)
Net income attributable to Medtronic
$4.8B
$4.7B
$3.7B
$3.8B
Basic earnings per share (in dollars per share)
$3.75
$3.63
$2.77
$2.83
Diluted earnings per share (in dollars per share)
$3.73
$3.61
$2.76
$2.82
Basic weighted average shares outstanding (in shares)
1.3B
1.3B
1.3B
1.3B
Diluted weighted average shares outstanding (in shares)
1.3B
1.3B
1.3B
1.3B
Medtronic Plc income statement, quarters
Line item
Jul 31, 2026 · Q1
Jan 23, 2026 · Q3
Oct 24, 2025 · Q2
Jul 25, 2025 · Q1
Net sales
$9.8B
$9.0B
$9.0B
$8.6B
Cost of products sold, excluding amortization of intangible assets
$3.4B
$3.3B
$3.1B
$3.0B
Research and development expense
$771.0M
$722.0M
$754.0M
$726.0M
Selling, general, and administrative expense
$3.2B
$3.0B
$3.0B
$2.8B
Amortization of intangible assets
$412.0M
$441.0M
$463.0M
$459.0M
Restructuring charges, net
$72.0M
$77.0M
$10.0M
$45.0M
Certain litigation charges, net
$0
$62.0M
$0
$27.0M
Other operating expense (income), net
$123.0M
$35.0M
$22.0M
$70.0M
Operating profit
$1.8B
$1.5B
$1.7B
$1.4B
Other non-operating expense (income), net
($190.0M)
($121.0M)
($92.0M)
($33.0M)
Interest expense, net
$186.0M
$181.0M
$181.0M
$176.0M
Income before income taxes
$1.8B
$1.4B
$1.6B
$1.3B
Income tax provision
$289.0M
$254.0M
$215.0M
$255.0M
Net income
$1.5B
$1.1B
$1.4B
$1.0B
Net income attributable to noncontrolling interests
($9.0M)
($6.0M)
($7.0M)
($7.0M)
Net income attributable to Medtronic
$1.5B
$1.1B
$1.4B
$1.0B
Basic earnings per share (in dollars per share)
$1.15
$0.89
$1.07
$0.81
Diluted earnings per share (in dollars per share)
$1.14
$0.89
$1.07
$0.81
Basic weighted average shares outstanding (in shares)
1.3B
1.3B
1.3B
1.3B
Diluted weighted average shares outstanding (in shares)
1.3B
1.3B
1.3B
1.3B
Balance sheet
Medtronic Plc balance sheet, fiscal years
Line item
Apr 24, 2026 · FY
Apr 25, 2025 · FY
Apr 26, 2024 · FY
Apr 28, 2023 · FY
Cash and cash equivalents
$1.9B
$2.2B
$1.3B
$1.5B
Investments
$7.3B
$6.7B
$6.7B
$6.4B
Accounts receivable, less allowance for credit losses of $190 and $199, respectively
$6.6B
$6.5B
$6.1B
$6.0B
Inventories
$6.0B
$5.5B
$5.2B
$5.3B
Other current assets
$3.0B
$2.9B
$2.6B
$2.4B
Total current assets
$24.8B
$23.8B
$21.9B
$21.7B
Property, plant, and equipment, net
$7.4B
$6.8B
$6.1B
$5.6B
Goodwill
$42.6B
$41.7B
$41.0B
$41.4B
Other intangible assets, net
$10.1B
$11.7B
$13.2B
$14.8B
Tax assets
$3.9B
$4.0B
$3.7B
$3.5B
Other assets
$4.1B
$3.6B
$4.0B
$4.0B
Total assets
$93.0B
$91.7B
$90.0B
$90.9B
Current debt obligations
$1.8B
$2.9B
$1.1B
$20.0M
Accounts payable
$2.6B
$2.4B
$2.4B
$2.7B
Accrued compensation
$2.7B
$2.5B
$2.4B
$1.9B
Accrued income taxes
$914.0M
$1.4B
$1.3B
$840.0M
Other accrued expenses
$3.6B
$3.7B
$3.6B
$3.6B
Total current liabilities
$11.7B
$12.9B
$10.8B
$9.1B
Long-term debt
$26.2B
$25.6B
$23.9B
$24.3B
Accrued compensation and retirement benefits
$1.2B
$1.2B
$1.1B
$1.1B
Accrued income taxes
$1.5B
$1.6B
$1.9B
$2.4B
Deferred tax liabilities
$362.0M
$403.0M
$515.0M
$708.0M
Other liabilities
$2.1B
$1.8B
$1.4B
$1.7B
Total liabilities
$43.0B
$43.4B
$39.6B
$39.3B
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,280,177,293 and 1,281,934,628 shares issued and outstanding, respectively
0
0
0
0
Additional paid-in capital
$20.9B
$20.8B
$23.1B
$24.6B
Retained earnings
$32.6B
$31.5B
$30.4B
$30.4B
Accumulated other comprehensive loss
($4.1B)
($4.3B)
($3.3B)
($3.5B)
Total shareholders’ equity
$49.5B
$48.0B
$50.2B
$51.5B
Noncontrolling interests
$609.0M
$232.0M
$206.0M
$182.0M
Total equity
$50.1B
$48.3B
$50.4B
$51.7B
Total liabilities and equity
$93.0B
$91.7B
$90.0B
$90.9B
Medtronic Plc balance sheet, quarters
Line item
Jul 31, 2026
Jan 23, 2026
Oct 24, 2025
Jul 25, 2025
Cash and cash equivalents
$1.7B
$1.1B
$1.3B
$1.3B
Investments
$7.1B
$7.2B
$7.0B
$6.8B
Accounts receivable, less allowances for credit losses of $203 and $190, respectively
$6.4B
$6.4B
$6.4B
$6.3B
Inventories
$6.2B
$6.3B
$6.2B
$5.9B
Other current assets
$3.0B
$3.0B
$3.1B
$3.0B
Total current assets
$24.4B
$24.1B
$24.0B
$23.2B
Property, plant, and equipment, net
$7.5B
$7.2B
$7.2B
$7.0B
Goodwill
$43.2B
$41.9B
$41.8B
$42.0B
Other intangible assets, net
$10.2B
$10.3B
$10.8B
$11.2B
Tax assets
$3.7B
$4.0B
$3.9B
$3.9B
Other assets
$4.3B
$4.0B
$3.7B
$3.6B
Total assets
$93.3B
$91.5B
$91.3B
$91.0B
Current debt obligations
$2.5B
$191.0M
$1.4B
$2.4B
Accounts payable
$2.7B
$2.6B
$2.6B
$2.6B
Accrued compensation
$1.9B
$2.6B
$2.1B
$2.0B
Accrued income taxes
$1.1B
$650.0M
$650.0M
$933.0M
Other accrued expenses
$3.6B
$3.5B
$3.2B
$3.6B
Total current liabilities
$11.8B
$9.5B
$9.9B
$11.5B
Long-term debt
$25.6B
$27.9B
$27.7B
$26.2B
Accrued compensation and retirement benefits
$1.2B
$1.2B
$1.2B
$1.2B
Accrued income taxes
$1.5B
$1.6B
$1.5B
$1.7B
Deferred tax liabilities
$349.0M
$365.0M
$386.0M
$416.0M
Other liabilities
$2.0B
$1.8B
$1.8B
$1.8B
Total liabilities
$42.5B
$42.3B
$42.5B
$42.8B
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,280,046,863 and 1,280,177,293 shares issued and outstanding, respectively
0
0
0
0
Additional paid-in capital
$20.8B
$21.0B
$20.9B
$20.9B
Retained earnings
$33.2B
$32.3B
$32.1B
$31.6B
Accumulated other comprehensive loss
($3.8B)
($4.3B)
($4.3B)
($4.6B)
Total shareholders’ equity
$50.2B
$49.0B
$48.7B
$47.9B
Noncontrolling interests
$618.0M
$211.0M
$204.0M
$240.0M
Total equity
$50.9B
$49.2B
$48.9B
$48.1B
Total liabilities and equity
$93.3B
$91.5B
$91.3B
$91.0B
Cash flow statement
Medtronic Plc cash flow statement, fiscal years
Line item
Apr 24, 2026 · FY
Apr 25, 2025 · FY
Apr 26, 2024 · FY
Apr 28, 2023 · FY
Net income
$4.8B
$4.7B
$3.7B
$3.8B
Depreciation and amortization
$3.0B
$2.9B
$2.6B
$2.7B
Provision for credit losses
$136.0M
$123.0M
$90.0M
$73.0M
Deferred income taxes
$51.0M
($316.0M)
($508.0M)
($226.0M)
Stock-based compensation
$457.0M
$429.0M
$393.0M
$355.0M
Asset impairments and related inventory write-downs
$0
$0
$371.0M
$0
Other, net
$314.0M
$310.0M
$573.0M
$270.0M
Accounts receivable, net
($200.0M)
($433.0M)
($391.0M)
($576.0M)
Inventories
($404.0M)
($292.0M)
($139.0M)
($939.0M)
Accounts payable and accrued liabilities
$46.0M
$209.0M
$391.0M
$696.0M
Other operating assets and liabilities
($865.0M)
($538.0M)
($345.0M)
($148.0M)
Net cash provided by operating activities
$7.3B
$7.0B
$6.8B
$6.0B
Acquisitions, net of cash acquired
($406.0M)
($98.0M)
($211.0M)
($1.9B)
Additions to property, plant, and equipment
($1.9B)
($1.9B)
($1.6B)
($1.5B)
Purchases of investments
($8.7B)
($8.2B)
($7.7B)
($7.5B)
Sales and maturities of investments
$8.1B
$8.5B
$7.4B
$7.3B
Other investing activities, net
($4.0M)
($249.0M)
($261.0M)
$4.0M
Net cash used in investing activities
($2.9B)
($1.9B)
($2.4B)
($3.5B)
Change in current debt obligations, net
$9.0M
($1.1B)
$1.1B
$0
Issuance of long-term debt
$1.7B
$3.2B
$0
$5.4B
Payments on long-term debt
($2.9B)
$0
$0
($6.0B)
Dividends to shareholders
($3.6B)
($3.6B)
($3.7B)
($3.6B)
Issuance of ordinary shares
516.0M
508.0M
284.0M
308.0M
Repurchase of ordinary shares
-1.0B
-3.2B
-2.1B
-645.0M
Proceeds from MiniMed initial public offering
$538.0M
—
—
—
Other financing activities, net
$44.0M
($184.0M)
($3.0M)
($409.0M)
Net cash used in financing activities
($4.8B)
($4.4B)
($4.5B)
($5.0B)
Effect of exchange rate changes on cash and cash equivalents
$85.0M
$188.0M
($230.0M)
$243.0M
Net change in cash and cash equivalents
($269.0M)
$934.0M
($259.0M)
($2.2B)
Cash and cash equivalents at beginning of period
$2.2B
$1.3B
$1.5B
$3.7B
Cash and cash equivalents at end of period
$1.9B
$2.2B
$1.3B
$1.5B
Income taxes
$1.9B
$1.8B
$1.6B
$1.5B
Interest
$774.0M
$762.0M
$826.0M
$606.0M
Medtronic Plc cash flow statement, quarters
Line item
Jul 31, 2026 · Q1
Jan 23, 2026 · YTD
Oct 24, 2025 · YTD
Jul 25, 2025 · Q1
Net income
$1.5B
$3.6B
$2.4B
$1.0B
Depreciation and amortization
$729.0M
$2.2B
$1.5B
$748.0M
Provision for credit losses
$25.0M
$102.0M
$66.0M
$28.0M
Deferred income taxes
$127.0M
$59.0M
$160.0M
$167.0M
Stock-based compensation
$125.0M
$362.0M
$268.0M
$86.0M
Other, net
($29.0M)
$280.0M
$167.0M
$159.0M
Accounts receivable, net
$224.0M
$87.0M
$74.0M
$288.0M
Inventories
($240.0M)
($803.0M)
($672.0M)
($373.0M)
Accounts payable and accrued liabilities
($531.0M)
($77.0M)
($780.0M)
($598.0M)
Other operating assets and liabilities
($118.0M)
($1.1B)
($1.2B)
($464.0M)
Net cash provided by operating activities
$1.8B
$4.8B
$2.0B
$1.1B
Acquisitions, net of cash acquired
($1.2B)
$0
—
—
Additions to property, plant, and equipment
($503.0M)
($1.4B)
($972.0M)
($504.0M)
Purchases of investments
($2.2B)
($6.6B)
($4.2B)
($2.1B)
Sales and maturities of investments
$2.2B
$6.0B
$4.0B
$2.0B
Other investing activities, net
$26.0M
($10.0M)
$14.0M
($125.0M)
Net cash used in investing activities
($1.6B)
($2.0B)
($1.2B)
($719.0M)
Change in current debt obligations, net
$812.0M
$173.0M
$1.4B
$649.0M
Payments on long-term debt
$0
($2.9B)
($2.9B)
($1.2B)
Dividends to shareholders
($921.0M)
($2.7B)
($1.8B)
($910.0M)
Issuance of ordinary shares
20.0M
419.0M
255.0M
95.0M
Repurchase of ordinary shares
-267.0M
-600.0M
-495.0M
-123.0M
Other financing activities, net
$13.0M
$60.0M
$65.0M
$70.0M
Net cash used in financing activities
($343.0M)
($3.9B)
($1.8B)
($1.4B)
Effect of exchange rate changes on cash and cash equivalents